Costs and outcomes associated with clopidogrel discontinuation in Medicare beneficiaries with acute coronary syndrome in the coverage gap.

Drug Healthc Patient Saf · 2012 · PMC3402012 · PMID 22826644

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

ACS and all-cause expenditure also showed a trend towards higher costs for those beneficiaries who discontinued clopidogrel compared with those who did not during their stay in the gap.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.